Clinical Trial Update: A Study of MDX-1100 in Subjects With Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 study of MDX-1100 in active ulcerative colitis conducted by Bristol-Myers Squibb has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• MDX-1100

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED